重组人粒细胞集落刺激因子用于不明原因复发性妊娠丢失女性:一项随机临床试验
本研究为随机双盲安慰剂对照试验,纳入150例不明原因复发性妊娠丢失女性,在英国21个中心开展,比较妊娠早期使用重组人粒细胞集落刺激因子(rhG-CSF)130 μg与安慰剂的疗效。结果显示,rhG-CSF组与安慰剂组20周临床妊娠率及活产率均无显著差异,RR为0.9(95%CI 0.7-1.2;P=0.48)。
要点
- rhG-CSF组20周临床妊娠率及活产率为59.2%(45/76),安慰剂组为64.9%(48/74)。
- 相对风险RR为0.9(95%CI 0.7-1.2;P=0.48),组间无显著差异。
- 次要结局包括流产、活产、不良事件等均无显著差异。
核心结论
- 妊娠早期给予rhG-CSF并未改善不明原因复发性妊娠丢失女性的妊娠结局。
研究设计与样本
- 随机、双盲、安慰剂对照临床试验,于2014年6月23日至2016年6月5日在英国21个复发性流产诊所开展,共纳入150例不明原因复发性妊娠丢失女性。
- 76例随机分配至rhG-CSF组,74例分配至安慰剂组;每日皮下注射rhG-CSF 130 μg或外观相同的安慰剂,从妊娠3至5周尽早开始,最长9周。
- 主要结局为妊娠20周经超声证实的临床妊娠;分析采用意向性治疗原则。
主要发现
- rhG-CSF组20周临床妊娠率及活产率为59.2%(45/76),安慰剂组为64.9%(48/74),相对风险RR为0.9(95%CI 0.7-1.2;P=0.48)。
- rhG-CSF组不良事件发生52例(68.4%),安慰剂组43例(58.1%)。
- 新生儿先天畸形在rhG-CSF组为1/46(2.1%),安慰剂组为1/49(2.0%),RR为0.9(95%CI 0.1-13.4;P=0.93)。
- 所有次要结局在组间均无显著差异的证据。
临床怎么用
- 作者认为,这是首个多中心研究及最大规模的随机临床试验,探讨人粒细胞集落刺激因子在复发性流产女性中的疗效与安全性。
- 与唯一可得的单中心随机对照试验不同,本试验显示妊娠早期使用rhG-CSF并未显著提高临床妊娠率或活产率。
局限性
- 本试验在诊断为不明原因复发性妊娠丢失的女性中开展,因此未进行(市售可得的)免疫功能障碍相关妊娠失败的筛查检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does administration of recombinant human granulocyte colony stimulating factor (rhG-CSF) in the first trimester improve pregnancy outcomes, among women with a history of unexplained recurrent pregnancy loss? SUMMARY ANSWER: rhG-CSF administered in the first trimester of pregnancy did not improve outcomes among women with a history of unexplained recurrent pregnancy loss. WHAT IS KNOWN ALREADY: The only previous randomized controlled study of granulocyte colony stimulating factor in recurrent miscarriage in 68 women with unexplained primary recurrent miscarriage found a statistically significant reduction in miscarriage and improvement in live birth rates. A further four observational studies where G-CSF was used in a recurrent miscarriage population were identified in the literature, two of which confirmed statistically significant increase in clinical pregnancy and live birth rates. STUDY DESIGN, SIZE, DURATION: A randomized, double-blind, placebo controlled clinical trial involving 150 women with a history of unexplained recurrent pregnancy loss was conducted at 21 sites with established recurrent miscarriage clinics in the United Kingdom between 23 June 2014 and 05 June 2016. The study was coordinated by University of Birmingham, UK. PARTICIPANTS/MATERIALS, SETTING, METHODS: One hundred and fifty women with a history of unexplained recurrent pregnancy loss: 76 were randomized to rhG-CSF and 74 to placebo. Daily subcutaneous injections of recombinant human granulocyte - colony stimulating factor 130 μg or identical appearing placebo from as early as three to five weeks of gestation for a maximum of 9 weeks. The trial used central randomization with allocation concealment. The primary outcome was clinical pregnancy at 20 weeks of gestation, as demonstrated by an ultrasound scan. Secondary outcomes included miscarriages, livebirth, adverse events, stillbirth, neonatal birth weight, changes in clinical laboratory variables following study drug exposure, major congenital anomalies, preterm births and incidence of anti-drug antibody formation. Analysis was by intention to treat. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 340 participants were screened for eligibility of which 150 women were randomized. 76 women (median age, 32[IQR, 29-34] years; mean BMI, 26.3[SD, 4.2]) and 74 women (median age, 31[IQR, 26-33] years; mean BMI, 25.8[SD, 4.2]) were randomized to placebo. All women were followed-up to primary outcome, and beyond to live birth. The clinical pregnancy rate at 20 weeks, as well as the live birth rate, was 59.2% (45/76) in the rhG-CSF group, and 64.9% (48/74) in the placebo group, giving a relative risk of 0.9 (95% CI: 0.7-1.2; P = 0.48). There was no evidence of a significant difference between the groups for any of the secondary outcomes. Adverse events (AEs) occurred in 52 (68.4%) participants in rhG-CSF group and 43 (58.1%) participants in the placebo group. Neonatal congenital anomalies were observed in 1/46 (2.1%) of babies in the rhG-CSF group versus 1/49 (2.0%) in the placebo group (RR of 0.9; 95% CI: 0.1-13.4; P = 0.93). LIMITATIONS, REASONS FOR CAUTION: This trial was conducted in women diagnosed with unexplained recurrent pregnancy loss and therefore no screening tests (commercially available) were performed for immune dysfunction related pregnancy failure/s. WIDER IMPLICATIONS OF THE FINDINGS: To our knowledge, this is the first multicentre study and largest randomized clinical trial to investigate the efficacy and safety of granulocyte human colony stimulating factor in women with recurrent miscarriages. Unlike the only available single center RCT, our trial showed no significant increase in clinical pregnancy or live births with the use of rhG-CSF in the first trimester of pregnancy. STUDY FUNDING/COMPETING INTEREST(S): This study was sponsored and supported by Nora Therapeutics, Inc., 530 Lytton Avenue, 2nd Floor, Palo Alto, CA 94301, USA. Darryl Carter was the co-founder and VP of research, Nora Therapeutics, Inc. and held shares in the company. He holds a patent for the use of recombinant human granulocyte colony stimulating factor to reduce unexplained recurrent pregnancy loss. Mark Joing, Paul Kwon and Jeff Tong were or are employees of Nora Therapeutics, Inc. No other potential conflict of interest relevant to this article was reported. TRIAL REGISTRATION NUMBER: EUDRACT No: 2014-000084-40; ClinicalTrials.gov Identifier: NCT02156063. TRIAL REGISTRATION DATE: 31 Mar 2014. DATE OF FIRST PATIENT’S ENROLMENT: 23 Jun 2014.
引用
- Eapen A, Joing M, Kwon P, et al. Recombinant human granulocyte- colony stimulating factor in women with unexplained recurrent pregnancy losses: a randomized clinical trial. Hum Reprod. 2019. PMID: 30776296. doi:10.1093/humrep/dey393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。